927802-39-9

Basic information

• Product Name: 2-(1,3-thiazol-2-yl)benzoic acid
• Synonyms: 2-(1,3-thiazol-2-yl)benzoic acid
• CAS NO: 927802-39-9
• Molecular Weight: 205.237
• Mol File: 927802-39-9.mol

Chemical Properties

• CAS DataBase Reference: 2-(1,3-thiazol-2-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1,3-thiazol-2-yl)benzoic acid(927802-39-9)
• EPA Substance Registry System: 2-(1,3-thiazol-2-yl)benzoic acid(927802-39-9)

Safety Data

• Hazardous Substances Data: 927802-39-9(Hazardous Substances Data)

Upstream product

• 269409-99-6 ethyl 2-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzoate 
• 223575-69-7 2-(2-thiazolyl)benzaldehyde 

Downstream Products

• 1078711-93-9 N-{(3-exo)-8-[(6-fluoro-2-naphthyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-(1,3-thiazol-2-yl)benzamide 

Relevant articles and documents

Heterocyclic Compound

The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Preparation method of (5-halogenothiazole-2-yl) benzoic acid compounds

The invention discloses a preparation method of (5-halogenothiazole-2-yl) benzoic acid compounds. The method comprises the steps of firstly synthesizing thiazole benzoate compounds by taking 2-bromine thiazole as a raw material, then halogenating and hydr

Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition

In our previous study on discovering novel types of CCR3 antagonists, we found a fluoronaphthalene derivative (1) that exhibited potent CCR3 inhibitory activity with an IC50 value of 20 nM. However, compound 1 also inhibited human cytochrome P450 2D6 (CYP2D6) with an IC50 value of 400 nM. In order to reduce its CYP2D6 inhibitory activity, we performed further systematic structural modifications on 1. In particular, we focused on reducing the number of lipophilic moieties in the biphenyl part of 1, using C log D7.4 values as the reference index of lipophilicity. This research led to the identification of N-{(3-exo)-8-[(6-fluoro-2-naphthyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl}-3-(piperidin-1-ylcarbonyl)isonicotinamide 1-oxide (30) which showed comparable CCR3 inhibitory activity (IC50 = 23 nM) with much reduced CYP2D6 inhibitory activity (IC50 = 29,000 nM) compared with 1.